152 related articles for article (PubMed ID: 34822501)
41. MS/MS-Based Molecular Networking Approach for the Detection of Aplysiatoxin-Related Compounds in Environmental Marine Cyanobacteria.
Ding CYG; Pang LM; Liang ZX; Goh KKK; Glukhov E; Gerwick WH; Tan LT
Mar Drugs; 2018 Dec; 16(12):. PubMed ID: 30551660
[TBL] [Abstract][Full Text] [Related]
42. Wewakamide A and guineamide G, cyclic depsipeptides from the marine cyanobacteria Lyngbya semiplena and Lyngbya majuscula.
Han B; Gross H; McPhail KL; Goeger D; Maier CS; Gerwick WH
J Microbiol Biotechnol; 2011 Sep; 21(9):930-6. PubMed ID: 21952369
[TBL] [Abstract][Full Text] [Related]
43. The pharmacophore of debromoaplysiatoxin responsible for protein kinase C activation.
Kong FH; Kishi Y; Perez-Sala D; Rando RR
Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1973-6. PubMed ID: 2000401
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and biological activities of simplified aplysiatoxin analogs focused on the CH/π interaction.
Kobayashi T; Yanagita RC; Irie K
Bioorg Med Chem Lett; 2020 Dec; 30(24):127657. PubMed ID: 33130291
[TBL] [Abstract][Full Text] [Related]
45. Drug discoveries towards Kv1.5 potassium channel.
Yang Q; Wang X; Du L; Li M; You Q
Curr Top Med Chem; 2009; 9(4):339-47. PubMed ID: 19442205
[TBL] [Abstract][Full Text] [Related]
46. A new lyngbyatoxin from the Hawaiian cyanobacterium Moorea producens.
Jiang W; Zhou W; Uchida H; Kikumori M; Irie K; Watanabe R; Suzuki T; Sakamoto B; Kamio M; Nagai H
Mar Drugs; 2014 May; 12(5):2748-59. PubMed ID: 24824022
[TBL] [Abstract][Full Text] [Related]
47. Benderamide A, a Cyclic Depsipeptide from a Singapore Collection of Marine Cyanobacterium cf.
Ding CYG; Ong JFM; Goh HC; Coffill CR; Tan LT
Mar Drugs; 2018 Oct; 16(11):. PubMed ID: 30373109
[TBL] [Abstract][Full Text] [Related]
48. Nhatrangins A and B, aplysiatoxin-related metabolites from the marine cyanobacterium Lyngbya majuscula from Vietnam.
Chlipala GE; Pham HT; Nguyen VH; Krunic A; Shim SH; Soejarto DD; Orjala J
J Nat Prod; 2010 Apr; 73(4):784-7. PubMed ID: 20373744
[TBL] [Abstract][Full Text] [Related]
49. Cyanolide A, a glycosidic macrolide with potent Molluscicidal activity from the Papua New Guinea cyanobacterium Lyngbya bouillonii.
Pereira AR; McCue CF; Gerwick WH
J Nat Prod; 2010 Feb; 73(2):217-20. PubMed ID: 20131814
[TBL] [Abstract][Full Text] [Related]
50. Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5.
Jeong I; Choi BH; Hahn SJ
Pflugers Arch; 2010 Oct; 460(5):851-62. PubMed ID: 20734202
[TBL] [Abstract][Full Text] [Related]
51. Dragonamide E, a modified linear lipopeptide from Lyngbya majuscula with antileishmanial activity.
Balunas MJ; Linington RG; Tidgewell K; Fenner AM; Ureña LD; Togna GD; Kyle DE; Gerwick WH
J Nat Prod; 2010 Jan; 73(1):60-6. PubMed ID: 20030365
[TBL] [Abstract][Full Text] [Related]
52. Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode.
Strutz-Seebohm N; Gutcher I; Decher N; Steinmeyer K; Lang F; Seebohm G
Cell Physiol Biochem; 2007; 20(6):791-800. PubMed ID: 17982261
[TBL] [Abstract][Full Text] [Related]
53. The Asymmetric Total Synthesis and Configuration Confirmation of Aplysiaenal and Nhatrangin A, Truncated Derivatives of Aplysiatoxin and Oscillatoxin.
Morishita M; Hada K; Kita M; Nishikawa T
J Nat Prod; 2023 Apr; 86(4):1033-1041. PubMed ID: 36999535
[TBL] [Abstract][Full Text] [Related]
54. [Effects of telmisartan on voltage-gated Kv1.3 and Kv1.5 potassium channels expressed in Xenopus oocytes].
Li MW; Wang XP; Gao CY; Zou AR
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Feb; 37(2):165-8. PubMed ID: 19719998
[TBL] [Abstract][Full Text] [Related]
55. Total structure determination of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscula.
Luesch H; Yoshida WY; Moore RE; Paul VJ; Corbett TH
J Am Chem Soc; 2001 Jun; 123(23):5418-23. PubMed ID: 11389621
[TBL] [Abstract][Full Text] [Related]
56. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
Karczewski J; Kiss L; Kane SA; Koblan KS; Lynch RJ; Spencer RH
Biochem Pharmacol; 2009 Jan; 77(2):177-85. PubMed ID: 18955031
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: mode of action.
Fischer F; Vonderlin N; Zitron E; Seyler C; Scherer D; Becker R; Katus HA; Scholz EP
Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):991-9. PubMed ID: 23832378
[TBL] [Abstract][Full Text] [Related]
58. The third class of new tumor promoters, polyacetates (debromoaplysiatoxin and aplysiatoxin), can differentiate biological actions relevant to tumor promoters.
Fujiki H; Suganuma M; Nakayasu M; Hoshino H; Moore RE; Sugimura T
Gan; 1982 Jun; 73(3):495-7. PubMed ID: 7129014
[TBL] [Abstract][Full Text] [Related]
59. The toxins of Lyngbya majuscula and their human and ecological health effects.
Osborne NJ; Webb PM; Shaw GR
Environ Int; 2001 Nov; 27(5):381-92. PubMed ID: 11757852
[TBL] [Abstract][Full Text] [Related]
60. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.
Gross MF; Castle NA; Zou A; Wickenden AD; Yu W; Spear KL
Bioorg Med Chem Lett; 2009 Jun; 19(11):3063-6. PubMed ID: 19398199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
